Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads MRI scans to spot hidden sarcomas

NCT ID NCT06073314

Diagnosis Sponsor: The Leeds Teaching Hospitals NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether artificial intelligence (AI) can help doctors tell the difference between cancerous and non-cancerous soft tissue lumps using MRI scans. 186 patients with soft tissue masses had extra MRI images taken. The AI was trained to identify which lumps were sarcoma and how aggressive they were. The goal is to make diagnosis faster and more accurate without needing a biopsy every time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

186 people

The number who actually took part.

Started

Aug 2023

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who have been referred for MRI for a soft tissue mass that may be a soft tissue sarcoma, and have not yet undergone treatment for the lesion.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with a soft tissue mass that are discussed at the sarcoma multi-disciplinary meeting 2. Undergoing MRI as part of their standard of care 3. Participant is willing and able to give informed consent for participation in the trial. Exclusion Criteria: 1. Patient has already had the mass, or part of the mass, surgically removed prior to their MRI scan 2. Contraindication to MRI (e.g. presence of contraindicated implants e.g. cardiac pacemakers, claustrophobia).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sarcoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sarcoma

Contacts and locations

Locations

  • Leeds Teaching Hospitals

    Leeds, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.